1. Hamburg meeting – April, 1. 2000

   Foreword Pages: I1 - I2

2. Sudden death: ACE inhibitors and beta-blockers

   • M.J. Landray

   Pages: I37 - I40

3. Coronary artery disease: an inflammatory or infectious process

   • J. Jahn
   • K. Dalhoff
   • H.A. Katus

   Pages: I59 - I64

4. Achieving optimal beta₁-blockade with metoprolol CR/Zok

   • J. Wikstrand

   Pages: I46 - I51

5. Renal disease as a risk factor for cardiovascular disease

   • F.C. Luft

   Pages: I72 - I76

6. The background of the MERIT-HF trial

   • R. Dietz
   • K.J. Osterziel
   • R. v.Harsdorf

   Pages: I84 - I89

7. MERIT-HF mortality and morbidity data

   • Å. Hjalmarson
   • B. Fagerberg
   • on behalf of the MERIT-HF Study Group

   Pages: I98 - I103

8. The management of heart failure – an overview

   • E. Erdmann

   Pages: I3 - I7

9. Beta-blockers: recognising the assets in relation to coronary artery disease

   • M.J. Kendall

   Pages: I31 - I36

10. Coronary artery disease: the role of lipids, hypertension and smoking

    • U. Keil

    Pages: I52 - I58

11. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?

    • Å. Hjalmarson

    Pages: I41 - I45

12. Coronary artery disease – free radical damage, antioxidant protection and the role of homocysteine

    • S.R.J. Maxwell

    Pages: I65 - I71

13. MERIT-HF – description of the trial

    • J. Wikstrand
    • on behalf of the MERIT-HF Study Group

    Pages: I90 - I97

14. ACE inhibitors in heart failure: an update

    • W.H.T. Smith
    • S.G. Ball

    Pages: I8 - I14

15. Clinical trial data on the cardioprotective effects of beta-blockade

    • M.J. Kendall

    Pages: I25 - I30

16. Treatment of heart failure with beta-blockers. Mechanisms and results

    • M. Böhm
    • C. Maack

    Pages: I15 - I24

17. Coronary artery disease – is menopause a risk factor?

    • C. Gohlke-Bärwolf

    Pages: I77 - I83